• Solid Corporate Earnings of Indonesia's Large Cap Stocks in Q1-2017

    A number of Indonesian big cap stocks have already released their first quarter 2017 corporate earnings. Most of them show good results and therefore the majority of analysts agree that full-year 2017 corporate earnings of Indonesian companies listed on the Indonesia Stock Exchange should, generally, be good, especially considering economic growth of Indonesia is expected to accelerate further in the remainder of the year. However, some stocks have become expensive particularly after the recent strong performance of Indonesian stocks.

    Lanjut baca ›

  • Indonesian Energy Companies in Focus: ABM Investama

    Indonesia Investments updated the company profile of ABM Investama in the Indonesian companies section. ABM Investama, listed on the Indonesia Stock Exchange, is an Indonesia-based holding company that is primarily focused on energy-related sectors, covering coal production, mining contractor services, and power solutions. After two years of net losses the company posted net profit of USD $12.89 million in 2016 supported by cost efficiency improvements in all business lines and the surging coal price in the second half of 2016.

    Lanjut baca ›

  • What is the Impact of Trump's Corporate Tax Reforms on Indonesia?

    The economies of Indonesia and other countries in Southeast Asia may feel the impact of US President Donald Trump's impending tax reforms. Currently markets are focused on these reforms. On Wednesday (26/04) Trump is set to propose steep cuts in US corporate taxes (from 35 percent to 15 percent) and the tax rate on offshore earnings that are repatriated (from 35 percent to 10 percent), while individual taxes will be simplified. These proposals will require US Congress approval before implementation.

    Lanjut baca ›

  • Kalbe Farma to Produce Erythropoietin (EPO) for Indonesia

    Kalbe Farma, Indonesia's largest pharmaceutical company, is set to start marketing its erythropoietin product (also known as EPO) domestically. Starting from mid-2018 Kalbe Farma will produce EPO, one of the raw materials for the production of medicines to treat cancer and kidney disease. The pharmaceutical company will become the first publicly listed company on the Indonesia Stock Exchange that produces EPO.

    Lanjut baca ›